A multicenter, prospective Phase IV observational study known as ARGOS evaluated the long-term real-world performance of Durysta (bimatoprost intracameral implant) in patients with open-angle glaucoma or ocular hypertension. Conducted across 32 U.S. centers, the study enrolled 217 patients (341 eyes), aiming to understand how a single Durysta implant performs in routine practice. At six months, 88.6% of treated eyes did not require additional intraocular pressure (IOP)-lowering therapy, a rate that only slightly declined to 83.7% at 12 months and 77.7% at 18 months. Mean IOP reductions ranged from –1.0 to –2.0 mmHg, and the average number of topical medications dropped from 1.8 to approximately 1.0 by month 18. The most frequent adverse events were mild increases in IOP and dry eye symptoms. Importantly, while prior studies raised concerns about endothelial cell loss with repeat dosing, the ARGOS findings affirm that a single administration maintains an acceptable safety profile. These findings highlight Durysta’s utility in patients with medication adherence issues or intolerance to topical therapies.

Citation:
https://www.reviewofophthalmology.com/article/longterm-data-support-durysta-in-realworld-glaucoma-care

Implications:
This study reinforces Durysta’s role as a durable and safe option for glaucoma patients needing nonadherence solutions. Its multimonth efficacy with minimal safety concerns supports its continued integration into clinical practice, particularly as a single-use strategy.